AutotacBio develops first-in-class therapeutics via targeted protein degradation of pathological proteins in a wide variety of human and canine diseases, including neurodegeneration and cancer. This is made possible by the AUTOTAC (AUTOphagy-TArgeting Chimera) platform, which simultaneously reactivates selective autophagy that is commonly inhibited in human diseases.